Sugi Predict

Sugi Predict / Compounds / SCHEMBL1266352

SCHEMBL1266352

SCHEMBL1266352

Cc1cc(Nc2c(C(=O)N3CC[C@H](N(C)C)C3)sc3c2ccc(=O)n3-c2ccccc2)ccc1F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 3/20 0.39
▸ KDR P35968 3/20 0.39
▸ BTK Q06187 1/20 0.36
▸ NSD2 O96028 1/20 0.36
▸ SETD2 Q9BYW2 1/20 0.36
▸ CDK1 P06493 2/20 0.36
▸ CDK2 P24941 2/20 0.36
▸ PARP1 P09874 1/20 0.36
▸ HTR7 P34969 1/20 0.35
▸ NTRK1 P04629 2/20 0.35
▸ KDM1A O60341 2/20 0.34
▸ MAOA P21397 2/20 0.34
▸ MAOB P27338 2/20 0.34
▸ MST1R Q04912 1/20 0.34
▸ PDK2 Q15119 1/20 0.34
▸ HRH3 Q9Y5N1 3/20 0.33
▸ USP2 O75604 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ BUB1 O43683 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1266952 1.00 MET (0.39) METKDRBTKNSD2SETD2
SCHEMBL1266092 0.91 MET (0.32) METKDRUSP2ALDH1A1MAPT
SCHEMBL1265696 0.90 CXCR1 (0.36) KDRUSP2ALDH1A1MAPT
SCHEMBL3837191 0.90 CXCR1 (0.36) KDRUSP2ALDH1A1MAPT
SCHEMBL1266937 0.90 CXCR1 (0.36) KDRUSP2ALDH1A1MAPT
SCHEMBL1266466 0.89 BTK (0.35) BTKHTR7NTRK1KDM1AUSP2
SCHEMBL1265999 0.89 BTK (0.35) BTKHTR7NTRK1KDM1AUSP2
SCHEMBL3830940 0.89 ALDH1A1 (0.37) BTKUSP2ALDH1A1MAPT
SCHEMBL1267284 0.86 ADORA2B (0.35) USP2ALDH1A1MAPT
SCHEMBL1266507 0.85 HTR7 (0.37) METKDRBTKPARP1HTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7521460-B2 Thienopyridone derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2009-04-21 — — US claimed
US-20070099894-A1 e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor CELLTECH R&D LIMITED (GB) 2007-05-03 — — US claimed
US-20110034495-A1 Method of Modulating Stress-Activated Protein Kinase System INTERMUNE, INC. (US) 2011-02-10 — — US disclosed
US-7521460-B2 Thienopyridone derivatives as kinase inhibitors UCB PHARMA S.A. (BE) 2009-04-21 — — US disclosed
US-20070099894-A1 e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor CELLTECH R&D LIMITED (GB) 2007-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034495-A1 Method of Modulating Stress-Activated Protein Kinase System MAPKAPK2, MAP3K6, MAP3K2 MET 1776/4885KDR 2900/4885BTK 541/4885
US-20070099894-A1 e.g. 3-[(2,4-Difluorophenyl)amino]-2-{[(2R)-2-(hydroxymethyl)pyrrolidin-1-yl]carbonyl}-7-phenylthieno[2,3-b]pyridin-6(7H)-one; autoimmune, neurodegenerative disorders, antiinflammatory agent; p38 MAP kinase inhibitor MAPK1, MAPKAPK2, MAPK6 MET 2901/4885KDR 3085/4885BTK 1041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.